The role of PGE2 and EP receptors on lung's immune and structural cells; possibilities for future asthma therapy.

Dominik Cebulla, Chiel van Geffen, Saeed Kolahian

Pharmacology & therapeutics 2023 Jan

filter terms:

Asthma is the most common airway chronic disease with treatments aimed mainly to control the symptoms. Adrenergic receptor agonists, corticosteroids and anti-leukotrienes have been used for decades, and the development of more targeted asthma treatments, known as biological therapies, were only recently established. However, due to the complexity of asthma and the limited efficacy as well as the side effects of available treatments, there is an urgent need for a new generation of asthma therapies. The anti-inflammatory and bronchodilatory effects of prostaglandin E2 in asthma are promising, yet complicated by undesirable side effects, such as cough and airway irritation. In this review, we summarize the most important literature on the role of all four E prostanoid (EP) receptors on the lung's immune and structural cells to further dissect the relevance of EP2/EP4 receptors as potential targets for future asthma therapy. Copyright © 2022 Elsevier Inc. All rights reserved.

Citation

Dominik Cebulla, Chiel van Geffen, Saeed Kolahian. The role of PGE2 and EP receptors on lung's immune and structural cells; possibilities for future asthma therapy. Pharmacology & therapeutics. 2023 Jan;241:108313